Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists

NCT07546981 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

554

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: Experimental: Participant Group CHF 5993 pMDI HFA-152a
OTHER: Active Comparator: CHF 1535 100/6 μg pMDI HFA-134a

Sponsor

Chiesi Farmaceutici S.p.A.